CD274 and non-small cell lung carcinoma: Neoadjuvant therapy can reduce tumor burden, increase R0 rate and improve survival rate.In recent years, with the emergence of PD-L1 inhibitors, the strategy of chemotherapy combined with PD-L1 inhibitors has changed the treatment prospects of non-small cell lung cancer [6–8].